Skip over main navigation
  • Sign up
  • Log in
  • Basket: (0 items)
The Perth Blood Institute Limited
  • Perth Blood Institute
  • Thrombosis Australia
  • Thrombosis Australia Professionals
  • Search
  • Facebook
  • Linkedin
  • Email
  • Search
  • Facebook
  • Linkedin
  • Email
Subscribe Donate
Menu
  • Who we are
    • Vision, mission and values
    • What we do
    • Our facilities
    • Our team
      • Board
      • Key staff
      • Investigators
      • Patrons and ambassadors
      • Thrombosis Australia Advisory Panel
    • Work with us
  • Our clinical trials
    • Clinical trials
    • Collaborations
    • Participate in a clinical trial
  • Our research
    • Current research projects
    • Research highlights
    • Research collaborations
      • PBI
      • APTIN
    • Participate in a research project
  • Support and resources
    • For patients and families
    • Useful links
  • Our impact
    • Stories
  • Get involved
    • Donate
    • Appeals
    • Fundraise for us
    • Volunteer
    • Partner with us
    • Partners and Supporters
    • Make a bequest
    • User Feedback
  • News and events
    • News
    • Upcoming events
    • Past Events
    • Publications
  • Admin
    • Log in
  • Basket: (0 items)
  • research-highlights
  1. Our research
  2. Research highlights

Research highlights

Publications in leading medical journals

PBI’s active clinical research focuses on deep vein thrombosis, stroke, thrombophilia, thrombocytopenia, haemophilia A, recurrent miscarriage, Von Willebrand disease, leukaemia, lymphoma, myeloma, anaemia and iron overload. PBI’s research division, together with PBI’s clinical trials division, conducted early- and late-phase international clinical trials with new therapeutics developed through PBI’s clinical research.

The trials produced research publications in leading medical journals, including the Journal of Thrombosis and Haemostasis and the New England Journal of Medicine; and provided the basis for early access to new-targeted drugs for Australian patients.


Complex microRNA control of blood coagulation


An area of PBI's research is on the modification of next generation precision nucleic acid-based medicines (in collaboration with Dr Rakish Veedu), for the purpose of the treatment of blood diseases and other cancers. PBI’s research team was the first to understand the complex microRNA (miR) control of blood coagulation factors which led to the discovery of the proposed miR mechanism of oestrogen mediated thrombosis.

This research has resulted in new miR-based related blood diagnostic tests and miR-based therapies currently being developed.


Thrombotic Thrombocytopaenic Purpura

Thrombotic Thrombocytopaenic Purpura (TTP) is a rare and fatal disease caused by a deficiency of the Von Willebrand factor cleaving enzyme, ADAMTS-13. ADAMTS-13 deficiency can be hereditary, but more often is an acquired disorder due to the production of inhibitory autoantibodies. It occurs in around 20 patients per year per million people. The PBI research division leads the Asia Pacific Microangiopathy Thrombocytopaenia (APMAT) Network across 24 leading centres in the Asia Pacific (AP) to rapidly collect and bio-bank clinical material on a large number of patients with Thrombotic Microangiopathy. Our work has standardised diagnostic ADAMTS-13 testing in the AP region, and utilising the APMAT bio-bank we are exploring new diagnostic algorithms and developing new molecular testing.

Our understanding of the rare TTP disease has led to a proposal for further research on the disease and a global standardisation study of ADAMTS13 testing.


Chronic Lymphocytic Leukaemia

Bleeding is a common complication of advanced chronic lymphocytic leukaemia (CLL). PBI’s research discovered important cancer-related platelet dysfunctions, which could contribute to the exacerbated bleeding phenotype seen in CLL patients.  This could be particularly significant in malignant CLL clone and/or therapeutic interventions, where further impaired platelet function could be at play. One study examined Bruton’s tyrosine kinase inhibitors (eg. ibrutinib, acalabrutinib) and their effect on blood samples collected from patients. These drugs are known to inhibit platelet aggregation mediated by glycoprotein VI (GPVI) and other platelet signalling pathways. Furthermore, the study examined the anti-platelet effects of BH3 mimetics (eg. venetoclax), a less well understood property of the drug. CLL is associated with a broad platelet functional defect, which persists despite the clinical benefits of ibrutinib or venetoclax treatment.

Results of the study showed that ibrutinib, not venetoclax, induces additive inhibition of platelet function in CLL patients, that is not related to altered GPVI cleavage. Additionally, it was shown that clinically-utilised whole blood platelet function assays are capable of quantifying the degree of functional impairment in CLL patients - a world first observation made by PBI scientists.

Back to top

Showing 10 of 0

Latest

  • Thrombosis Australia Advisory Panel

    We have established an advisory panel to provide oversight and direction to Thrombosis Australia, to ensure that the information we provide is current and accurate.

  • Thrombosis Australia is now live!

    Thrombosis Australia is now live!

    Australians are set to benefit from a central resource ‘hub’ of authoritative information to increase awareness and understanding of deep vein thrombosis, pulmonary embolism and stroke, and improve their prevention, early detection and management.

  • Breakthrough for haemophilia A patients

    Breakthrough for haemophilia A patients

    Perth Blood Institute has participated in a ground-breaking clinical trial which has uncovered a new life-changing treatment for people with haemophilia.

  • Darren's Story

    Darren's Story

    Darren suffered his first experience with blood clots on April 12th, 2015. Darren arrived at the hospital emergency department in a very bad way, even unable to speak. Read more about Darren's story.

Most read

  • Alicia's Story

    Alicia's Story

    Alicia was a very active and healthy 19-year-old when during a social game of netball, she rolled her ankle and was diagnosed with ligament damage. Learn more about Alicia's experience here.

  • Accessibility

  • COVID-19 and Thrombosis

    COVID-19 and Thrombosis

    The International Society of Thrombosis and Haemostasis has released information on COVID-19 and thrombosis. Here are the important facts; Having a blood clot does not increase your risk of acquiring COVID-19. Taking anticoagulants (blood-thinning medication) for a blood clot disorder also does not increase your risk of acquiring COVID-19.

  • Privacy Policy

    THE PERTH BLOOD INSTITUTE LIMITED ABN: 24164941815 (trading as Perth Blood Institute) takes your privacy seriously. We respect and uphold your right to privacy protection under the Australian Privacy Principles (APPs), by regulating the way in which we collect, use, disclose, hold and destroy your personal information. This Privacy Policy covers all personal information held by us.

  • Research Team Awarded DARF Dementia Grant

    Research Team Awarded DARF Dementia Grant

    Perth Blood Institute is pleased to announce it is the recipient of the Norma Beaconsfield Project Grant, awarded by the Dementia Australia Research Foundation (DARF). This grant will allow the Platelet Research Team to continue important investigations into the effect of blood-thinning medication on dementia risk.

  • Bridget's Story

    Bridget's Story

    When Bridget was 35, at 25 weeks gestation during her third pregnancy, she was diagnosed suddenly with a pulmonary embolism (PE) in her lungs. Read Bridget's story here.

  • Clinical Research Fellowship

    The Perth Blood Institute (PBI) conducts medical research into blood disorders, including their causes, prevention and treatment options; facilitates access to high quality clinical trials for people affected by blood disorders; and provides information about blood disorders to patients and their families.

  • Elie's Story

    Elie's Story

    When Elie was a young, fit and healthy 22-year-old he noticed a lump in the side of his neck. He went to his GP complaining of fatigue, insomnia, and severe itching. After being misdiagnosed with glandular fever and then a mystery virus, he received a call from his doctor.

  • COVID-19 - Impact on blood transfusions and blood donations

    COVID-19 - Impact on blood transfusions and blood donations

    Some members of the community may be concerned about the potential transmission of the COVID-19 virus through blood products, such as through blood transfusions. If you rely on blood products, you should feel confident to continue to receive them.

  • Terms and Conditions

Tag cloud

blood clots cancer chronic lymphocytic leukemia CLL contraceptive dementia haemophilia A leukemia Microangiopathic Thrombocytopenia multiple myeloma Non-Hodgkin Lymphoma pregnancy thrombosis Thrombotic Thrombocytopaenic Pupura Venous Thromboembolism VTE
Perth Blood Institute

Perth Blood Institute

Your donation can help PBI to fund vital translational research into blood disorders including thrombosis and haemophilia; support a clinical research investigation into the development of a new treatment or intervention; or help us develop educational programs to foster the next generation of career haematologists. Read more

Donate Fundraise

Published: 18th February, 2020

Updated: 4th May, 2020

Author:

Related topics:
  • Appeals

Sign up for our newsletter

Please enter your first name
Please enter your last name
Please enter your email address Please enter a valid email address (e.g. [email protected])

Helpful links

  • Sitemap
  • Accessibility
  • Terms & conditions
  • Privacy policy
  • Contact us

Contact

18 Prowse Street
West Perth
WA 6005
P : +61 8 9200 5300
F : +61 8 9200 5324
E : [email protected]

  • Facebook
  • Instagram
  • Linkedin
  • Email

PBI is registered as an Income Tax Exempt Charity
CFN: CC21886
ACN: 164 941 815
ABN: 24 164 941 815

© Perth Blood Institute 2020